Dundee Research Interest Group

A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson’s disease.

Sponsor: Abbvie. 

Recruitment has stopped, trial ongoing.